PROTOCOL RTOG 1112 – Temporarily Closed to Accrual

RTOG 1112, “Randomized Phase III Study of Sorafenib versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma,” is temporarily closed to accrual effective immediately pending a protocol amendment to reinstate the radiation therapy risk profile in the sample consent. The radiation therapy risk profile was inadvertently removed in Amendment 6 (NCI version date May 13, 2019; broadcast date June 24, 2019).

 

NRG Oncology will send a broadcast to release the corrective amendment and reopen the study as soon as the amendment receives NCI approval.

 

Please distribute this information to the appropriate personnel at participating affiliate/NCORP component institutions.

Twitter
This message was sent from NRG-Broadcasts@NRGOncology.org to NRG-Broadcasts@NRGOncology.org
Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address | Forward Email | Report Abuse
View this email in your browser
You are receiving this email because of your relationship with NRG Oncology. Please reconfirm your interest in receiving emails from us. If you do not wish to receive any more emails, you can unsubscribe here.